{
  "ticker": "CSL.AX",
  "company": "CSL Limited",
  "sector": "Healthcare",
  "market_cap": "138.5B",
  "hypotheses": {
    "N1": {
      "label": "Growth/Recovery",
      "description": "Plasma collections normalise; Vifor acquisition delivers synergies; pipeline catalysts",
      "plain_english": "CSL's plasma collection business is recovering from COVID disruption, and its recent acquisition of Vifor Pharma is starting to deliver cost savings. If both trends continue, earnings growth could accelerate beyond current expectations.",
      "what_to_watch": "H1 FY26 plasma collection volumes and Vifor integration milestones. If plasma cost per litre returns to pre-COVID levels, this narrative strengthens significantly.",
      "upside": "Pipeline catalysts (CSL112, garadacimab) could drive re-rating if clinical data exceeds expectations.",
      "risk_plain": "If plasma collection costs stay elevated or Vifor integration hits unexpected problems, the growth story weakens.",
      "survival_score": 0.05,
      "status": "VERY_LOW",
      "weighted_inconsistency": 2.5,
      "last_updated": "2026-02-26T22:00:24.438Z"
    },
    "N2": {
      "label": "Managed/Base Case",
      "description": "Steady-state compounder: high single-digit earnings growth, premium valuation sustained",
      "plain_english": "CSL continues doing what it does best — growing earnings at 7-10% per year, driven by its dominant position in the global plasma market. The company deserves its premium valuation because of its deep competitive moat and long runway of growth.",
      "what_to_watch": "FY26 earnings guidance at H1 result. If guidance stays at 7-10% NPATA growth, the base case holds firm.",
      "upside": "Consistent execution could attract more long-only institutional capital, supporting valuation multiples.",
      "risk_plain": "If growth slips below high single digits, the premium valuation may not be sustainable.",
      "survival_score": 0.1,
      "status": "VERY_LOW",
      "weighted_inconsistency": 1,
      "last_updated": "2026-02-26T22:00:24.438Z"
    },
    "N3": {
      "label": "Risk/Downside",
      "description": "Vifor integration drags; plasma margin recovery slower than guided; FX headwinds",
      "plain_english": "Several things could go wrong at once: the Vifor acquisition might cost more to integrate than expected, plasma margins might not recover as fast as management promised, and the strong Australian dollar could eat into overseas earnings when converted back.",
      "what_to_watch": "Vifor integration costs in H1 FY26 and AUD/USD exchange rate trajectory. If integration costs rise or AUD strengthens above 0.70, downside risk increases.",
      "upside": null,
      "risk_plain": "Currency headwinds alone could knock 3-5% off reported earnings, and if combined with slower Vifor synergies, the stock could de-rate.",
      "survival_score": 0.48,
      "status": "MODERATE",
      "weighted_inconsistency": 4.2,
      "last_updated": "2026-02-26T22:00:24.438Z"
    },
    "N4": {
      "label": "Disruption",
      "description": "Gene therapy disrupts immunoglobulin demand; biosimilar erosion of key products",
      "plain_english": "This is the long-term existential risk: if gene therapy advances make immunoglobulin treatments unnecessary, or if biosimilar competitors undercut CSL's key products, the company's core business could face structural decline.",
      "what_to_watch": "Gene therapy clinical trial results targeting primary immunodeficiency conditions, and any biosimilar approvals for immunoglobulin products in major markets.",
      "upside": null,
      "risk_plain": "While this is a long-term risk, any breakthrough gene therapy result could trigger a sharp de-rating of the entire plasma sector.",
      "survival_score": 0.37,
      "status": "LOW",
      "weighted_inconsistency": 7.1,
      "last_updated": "2026-02-26T22:00:24.438Z"
    }
  },
  "dominant": "N3",
  "confidence": "MODERATE",
  "alert_state": "NORMAL",
  "alert_started": null,
  "current_price": 146.02,
  "big_picture": "CSL is a global biotech leader specialising in plasma-derived therapies and vaccines. It is one of only three companies worldwide that can collect and process blood plasma at scale, giving it an extremely strong competitive position.",
  "last_flip": {
    "date": "2026-02-26",
    "from": "N2",
    "to": "N3",
    "trigger": "Automated: survival score shift (Managed/Base Case → Risk/Downside)",
    "price_at_flip": 145.62,
    "from_survival": 0.27,
    "to_survival": 0.34
  },
  "narrative_history": [
    {
      "date": "2025-02-15",
      "from": "N2",
      "to": "N1",
      "trigger": "H1 FY25 earnings beat; Vifor synergies ahead of schedule; upgraded FY25 guidance",
      "price_at_flip": 305,
      "from_survival": 0.4,
      "to_survival": 0.78
    },
    {
      "date": "2025-08-20",
      "from": "N1",
      "to": "N2",
      "trigger": "FY25 result in-line but guidance conservative; plasma margin recovery on track but gradual",
      "price_at_flip": 278,
      "from_survival": 0.36,
      "to_survival": 0.72
    }
  ],
  "evidence_items": [
    {
      "id": "CSL_FY25_RESULT",
      "type": "EARNINGS_REPORT",
      "source": "ASX Filing",
      "epistemic_tag": "Under Oath (statutory)",
      "date": "2025-08-20T08:00:00+11:00",
      "summary": "FY25 NPATA $3.2B in-line; FY26 guidance 7-10% growth (conservative)",
      "diagnosticity": "HIGH",
      "hypothesis_impact": {
        "N1": "NEUTRAL",
        "N2": "CONSISTENT",
        "N3": "INCONSISTENT",
        "N4": "INCONSISTENT"
      },
      "decay": {
        "full_weight_days": 90,
        "half_life_days": 120
      },
      "active": true
    },
    {
      "id": "CSL_PLASMA_COLLECTIONS",
      "type": "OPERATIONAL_DATA",
      "source": "Investor Day",
      "epistemic_tag": "Motivated (corporate)",
      "date": "2025-11-10T10:00:00+11:00",
      "summary": "Plasma collections +15% YoY; cost per litre declining but above pre-COVID levels",
      "diagnosticity": "MEDIUM",
      "hypothesis_impact": {
        "N1": "CONSISTENT",
        "N2": "CONSISTENT",
        "N3": "INCONSISTENT",
        "N4": "NEUTRAL"
      },
      "decay": {
        "full_weight_days": 60,
        "half_life_days": 60
      },
      "active": true
    },
    {
      "id": "CSL_VIFOR_SYNERGIES",
      "type": "OPERATIONAL_DATA",
      "source": "Investor Day",
      "epistemic_tag": "Motivated (corporate)",
      "date": "2025-11-10T10:00:00+11:00",
      "summary": "Vifor synergies tracking to $200M target; iron portfolio growing 12% organically",
      "diagnosticity": "MEDIUM",
      "hypothesis_impact": {
        "N1": "CONSISTENT",
        "N2": "CONSISTENT",
        "N3": "INCONSISTENT",
        "N4": "NEUTRAL"
      },
      "decay": {
        "full_weight_days": 60,
        "half_life_days": 90
      },
      "active": true
    },
    {
      "id": "CSL_PIPELINE_UPDATE",
      "type": "CLINICAL_DATA",
      "source": "ASH Conference",
      "epistemic_tag": "Peer-reviewed (scientific)",
      "date": "2025-12-08T08:00:00+11:00",
      "summary": "Garadacimab Phase III positive for hereditary angioedema prevention; regulatory submission planned",
      "diagnosticity": "HIGH",
      "hypothesis_impact": {
        "N1": "CONSISTENT",
        "N2": "NEUTRAL",
        "N3": "INCONSISTENT",
        "N4": "INCONSISTENT"
      },
      "decay": {
        "full_weight_days": 120,
        "half_life_days": 180
      },
      "active": true
    },
    {
      "date": "2026-02-25",
      "type": "OVERCORRECTION_TRIGGER",
      "severity": "AMBER",
      "message": "Single-day move of -49.2% exceeds 10% threshold — possible overcorrection",
      "auto_generated": true
    }
  ],
  "price_signals": [
    {
      "date": "2026-02-24",
      "classification": "NOISE",
      "daily_change_pct": -0.04,
      "volume_multiplier": 1,
      "cumulative_5d": 0,
      "cumulative_20d": 1.42,
      "results_day": false,
      "overcorrection_active": false
    },
    {
      "date": "2026-02-25",
      "classification": "MATERIAL",
      "daily_change_pct": -49.23,
      "volume_multiplier": 1,
      "cumulative_5d": 0,
      "cumulative_20d": 1.42,
      "results_day": false,
      "overcorrection_active": true
    }
  ],
  "editorial_override": null,
  "price_history": [
    182.95,
    182.14,
    182.9,
    186.18,
    186.3,
    183.64,
    183.44,
    182.3,
    185.61,
    184.1,
    185.5,
    181.82,
    181.63,
    178.81,
    183.93,
    179.31,
    177.15,
    173.39,
    173.99,
    175.08,
    176.31,
    175.66,
    171.48,
    173.55,
    172.42,
    172.65,
    171.96,
    172.46,
    168.29,
    170,
    174.45,
    174.29,
    175.1,
    173.32,
    173.49,
    175.28,
    175.53,
    176.5,
    176.7,
    176.11,
    178.41,
    179.62,
    182.29,
    180.19,
    179.4,
    181.42,
    177.08,
    178.11,
    181.7,
    181.24,
    180.5,
    180.37,
    171.39,
    163.44,
    150.01,
    152.17,
    151.56,
    151.56,
    151.56,
    146.02
  ],
  "weighting": null,
  "three_layer_signal": {
    "company_signal": -28,
    "company_detail": {
      "method": "net_hypothesis_weights",
      "bull": 26,
      "bear": 54,
      "direction": "downside",
      "hypotheses": [
        {
          "title": "N1: Structural Compounder Resumes",
          "direction": "upside",
          "weight": 26
        },
        {
          "title": "N2: Execution Risk in Transformation",
          "direction": "downside",
          "weight": 31
        },
        {
          "title": "N3: Structural Headwinds Emerging",
          "direction": "downside",
          "weight": 23
        },
        {
          "title": "N4: M&amp;A or Corporate Event",
          "direction": "neutral",
          "weight": 20
        }
      ],
      "computed_at": "2026-02-24T07:54:21.306Z"
    },
    "overall_sentiment": -28,
    "sentiment_label": "DOWNSIDE",
    "method": "company_only",
    "composite_computed_at": "2026-02-24T07:54:38.661Z",
    "macro_signal": 0,
    "sector_signal": 0,
    "tech_signal": 0,
    "external_weight": 0
  },
  "risk_skew": "DOWNSIDE",
  "valuation_range": {
    "low": 246.16,
    "mid": 273.51,
    "high": 300.86,
    "shift_pct": -0.042,
    "signal_used": -28,
    "method": "sentiment_shift_v3",
    "computed_at": "2026-02-24T07:54:39.547Z"
  },
  "priceHistory": [
    145,
    145.62,
    146.02
  ],
  "freshness": {
    "pricePctChange": 0.3,
    "urgency": 0,
    "status": "OK",
    "badge": "ok"
  },
  "last_price_update": "2026-02-26T05:36:47.899Z",
  "technicalAnalysis": {
    "date": "11 February 2026",
    "period": "1 Year",
    "source": "Continuum Technical Intelligence",
    "regime": "Breakdown",
    "clarity": "Clear",
    "price": {
      "current": 146.02,
      "currency": "A$"
    },
    "movingAverages": {
      "ma50": {
        "value": 176.5,
        "date": "12 Feb 2026"
      },
      "ma200": {
        "value": 210,
        "date": "12 Feb 2026"
      },
      "crossover": {
        "type": "Death Cross",
        "date": "w/c 22 September 2025",
        "description": "50-day MA crossed below 200-day MA following sharp selloff; gap widening"
      },
      "priceVsMa50": -7.4,
      "priceVsMa200": -22.2
    },
    "trend": {
      "direction": "Down",
      "duration": "7 months",
      "structure": "Consolidation base broken by 1H FY26 results crash; new 8-year low at A$151",
      "peak": {
        "price": 272,
        "date": "w/c 28 July 2025"
      },
      "trough": {
        "price": 151.08,
        "date": "12 February 2026"
      },
      "drawdown": -44.4
    },
    "keyLevels": {
      "support": {
        "price": 151,
        "method": "Intraday 1H results crash low (12 Feb 2026); 8-year low"
      },
      "resistance": {
        "price": 175,
        "method": "Prior support turned resistance; former consolidation base"
      },
      "fiftyTwoWeekHigh": {
        "price": 272,
        "date": "w/c 28 July 2025"
      },
      "fiftyTwoWeekLow": {
        "price": 151.08,
        "date": "12 February 2026"
      }
    },
    "volume": {
      "latestVs20DayAvg": 5.8,
      "latestDate": "12 February 2026",
      "priorSpikes": [
        {
          "period": "w/c 1 September 2025",
          "ratio": 3.4,
          "context": "Sharp selloff from A$271 to A$225"
        },
        {
          "period": "w/c 27 October 2025",
          "ratio": 2.2,
          "context": "Break below A$200; institutional rebalancing"
        },
        {
          "period": "w/c 10 November 2025",
          "ratio": 2.8,
          "context": "Crash to A$170; capitulation selling"
        },
        {
          "period": "12 February 2026",
          "ratio": 5.8,
          "context": "1H FY26 results + CEO departure; crashed 17% intraday to A$151"
        }
      ]
    },
    "volatility": {
      "latestDailyRange": {
        "high": 180.5,
        "low": 151.08,
        "date": "12 February 2026"
      },
      "latestRangePercent": 19.5,
      "avgDailyRangePercent30": 2.1,
      "avgDailyRangePercent90": 1.9
    },
    "meanReversion": {
      "vsMa50": -7.4,
      "vsMa200": -22.2,
      "rangePosition": 10,
      "rangeHigh": 272,
      "rangeLow": 151.08
    },
    "inflectionPoints": [
      {
        "date": "w/c 28 July 2025",
        "price": 272,
        "event": "12-month high"
      },
      {
        "date": "w/c 1 September 2025",
        "price": 225.5,
        "event": "Sharp selloff; drops 17% in one week"
      },
      {
        "date": "w/c 22 September 2025",
        "price": 205.81,
        "event": "Death cross forms; 50-day MA below 200-day MA"
      },
      {
        "date": "w/c 10 November 2025",
        "price": 170.77,
        "event": "Breaks below A$180; near capitulation"
      },
      {
        "date": "w/c 12 January 2026",
        "price": 168.29,
        "event": "Prior 12-month low; base attempted"
      },
      {
        "date": "12 February 2026",
        "price": 151.08,
        "event": "1H results + CEO exit; crashed 17% intraday to 8-year low; recovered to A$163"
      }
    ],
    "relativePerformance": {
      "vsIndex": {
        "name": "S&amp;P/ASX 200",
        "period": "12 months",
        "stockReturn": -39.9,
        "indexReturn": 6.9,
        "relativeReturn": -46.8
      },
      "vsSector": {
        "name": "S&amp;P/ASX Healthcare",
        "period": "12 months",
        "stockReturn": -39.9,
        "sectorReturn": -24.9,
        "relativeReturn": -15
      }
    }
  },
  "price_evidence": {
    "last_run": "2026-02-26T22:00:24.438Z",
    "classification": "NOTABLE"
  },
  "last_research_update": "2026-02-26T22:00:24.438Z",
  "price": 146.02,
  "date": "26 February 2026"
}